Full title: Improving performance of polygenic risk scores for hypertension across two ancestry groups.

Short Title: Improving PRS for HTN across two ancestry groups.

Marguerite R. Irvin, PhD[1], Vinodh Srinivasasainagendra, MS[2], Nicole D. Armstrong, PhD[1], Amit Patki, MS[2], Ulrich Broeckel, MD[3], Zhe Wang[1], Leslie A. Lange, PhD[5], Nita A Limdi[6], Alicia Huerta-Chagoya [7,8,9,10], Joohyun Kim, PhD[11], Maggie C.Y. Ng, PhD [11], Josep M Mercader, PhD[7,8,9,10,12] , Hemant K. Tiwari, PhD[2]

[1]Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA
[2]Department of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA
[3]Section of Genomic Pediatrics, Department of Pediatrics, Children's Research Institute, The Medical College of Wisconsin, Milwaukee, WI, USA
[5]Department of Medicine, Division of Biomedical Informatics and Personalized Medicine, University of Colorado Anschutz Medical Campus, Denver, CO, USA
[6]Department of Neurology, Heersink School of Medicine, University of Alabama at Birmingham.
[7]Programs in Metabolism and Medical & Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
[8]Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.
[9]Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA.
[10]Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America.
[11]Vanderbilt Genetics Institute, Division of Genetic Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
[12] Novo Nordisk Foundation Center for Genomic Mechanisms of Disease, Broad Institute of MIT and Harvard, Cambridge, MA

Corresponding author
Marguerite R. Irvin, PhD, M.S.
Department of Epidemiology
University of Alabama at Birmingham
Birmingham, AL 35294
irvinr@uab.edu

Abstract

Polygenic risk score (PRS) methods are evolving, and the benefit of adding functional annotations to the variant weights has been especially promising. However, less attention has been given to how the linkage disequilibrium (LD) reference panel used affects the score performance. In the current study, we compared two Bayesian approaches, one that incorporates functional annotations (LDpred-funct) and one that does not (PRS-CS), extending these applications to the hypertension (HTN) trait across two ancestry groups (European Americans EA, and African Americans, AA). In PRS-CS we used the standard HapMap 3 LD (HM3) reference panel, as well as a modified multi-ancestry reference panel (TagIt) with better coverage of variants from multiple ancestries. Individual-level data in 1,533 EA (58% with HTN) and 8,603 AA (71% with HTN) participants from the Reasons for Geographic and Racial Differences in Stroke Study (REGARDS) was used to optimize scores across the two approaches. PRS performance metrics including R^2 and odds ratios (OR) per standard deviation (SD) were then used to assess PRS performance in 1,270 EA (55% with HTN) and 1,896 AA (69% with HTN) participants from the Hypertension Genetic Epidemiology Network Study (HyperGEN). Among EAs in HyperGEN we observed an R^2 of 6.0% for LD-Pred-funct and R^2 of 7.3% for PRS-CS-TagIt versus R^2 of 1.4% for PRS-CS-HM3. The magnitude of the OR per SD for HTN was also higher for PRS-CS-TagIt OR=2.17 (95% CI 1.65-2.85, $p=3.0*10^{-8}$) and LD-Pred-funct OR=2.14 (95% CI 1.61-2.85, $p=1.46*10^{-7}$) versus PRS-CS-HM3 (OR=1.40; 95% CI 10.8-1.82). Among AAs in HyperGEN, the improvements were more modest, where we observed R^2 of 1.9% for LD-Pred-funct and R^2 of 2.9% for PRS-CS-TagIt versus 0.7% for PRS-CS-HM3. We found that both annotations and the updated LD panel improved the scores in both ancestry groups, but did not make the scores more equitable across the groups.

Author Summary

Genomics can aid in risk prediction and prevention. Polygenic risk score (PRS) development and application is becoming more popular because there's a lot of genetic data available for training PRS, and they have the potential to be useful in healthcare. However, PRS are not yet widely used in clinics, and the methods are still developing. Early PRS methods only used certain genetic markers, but newer ones use more data and better models to try to predict disease risk more accurately. Still, these tools often don’t work as well for people from underrepresented populations, which could increase health inequalities. Researchers are trying to fix this by using more up-to-date data and adding extra information about how genes function. In our study of HTN, we investigated newer approaches which made PRS more accurate for both for African American individuals and European American individuals—but they didn’t fully close the performance gap between the groups.

Introduction

Genome-wide association studies (GWAS) have uncovered a great deal about the polygenic architecture of common complex disorders. Although GWAS results have been largely challenging to translate into clinical settings, applications involving polygenic risk scores (PRS) show promise for clinical utility.(1) Methods for PRS are evolving, and standard pipelines for derivation and implementation have been proposed but are not yet established.(2) Other challenges include the varying performance of PRS across populations with diminished predictive capacity in minority populations.(3) This is most likely due to linkage disequilibrium (LD) patterns that vary across populations, and the overrepresentation of European Ancestry individuals (EAs) in genetic databases leveraged to create PRS. Strategies for improving performance are emerging but may still leave some ancestry groups behind. (4)

Currently, there is no standard method for polygenic prediction. Common approaches include pruning and thresholding (P+T) which sums the effect size of variants filtered on LD and evidence of association.(5) Alternatively, Bayesian polygenic prediction methods aim to capture variants genome-wide and, thus, do not attempt to identify a minimal subset of variants, but shrink their effects based on their LD.(6-9) These methods use prior distributions paired with advanced modeling techniques, GWAS summary statistics, and an external LD reference panel to estimate the posterior mean effect sizes. For instance, the PRS-CS method uses continuous shrinkage priors to enable SNP-specific adaptive shrinkage while allowing for diverse underlying genetic architectures across SNPs.(6) Another widely used method, LDPred, applies a point-normal prior for the SNP effect sizes after assuming there is an optimized proportion of causal variants for the trait of interest. (8, 10) Functional annotations can help prioritize more causal variants and LDPred has been extended to LDpred-funct by adding functional annotation information to the priors to estimate the mean causal effect sizes.(11)

While many comparisons have been made between PRS development approaches, the benefit of adding functional annotations to available methods is becoming increasingly evident.

As functional annotations may be more likely to differentiate causal SNPs from non-causal SNPs in high LD, they may help harmonize translation performance across ancestral groups. (12) Less attention has been given to the impact the chosen LD reference panel has on the variant's selection process. Expanding the variants available in the leveraged multi-ancestry reference panel may improve PRS performance by better capturing linkage disequilibrium patterns across diverse populations. In the current study, we compared LDpred-funct performance to PRS-CS, which does not include functional annotations, extending these applications to hypertension (HTN) across two ancestry groups (European Ancestry, EA and African Ancestry, AA). In the PRS-CS program, we utilized the standard HapMap 3 (HM3) LD reference panel, as well as a modified multi-ancestry reference panel (TagIt) with a better coverage of variants from multi-ancestry populations. (13) Our study assessed these methods using individual-level data in 1,598 EA and 8,603 AA participants with GWAS from the Reasons for Geographic and Racial Differences in Stroke Study (REGARDS) and 1,270 EA and 1,896 AA participants with GWAS from the Hypertension Genetic Epidemiology Network Study (HyperGEN).(14, 15) For each approach, REGARDS served as the optimization cohort and HyperGEN as the validation cohort.

Results

Demographic data for the testing and validation cohorts is provided in **Table 1**. REGARDS participants on average were older than HyperGEN participants. Both cohorts had a higher percentage of females and larger case versus control counts due to the older (REGARDS) and hypertensive population (HyperGEN) sampling. The count of variants per score are presented in **Table 2** with fewer variants included for the PRS-CS method (~800K-2M variants) and close to three times more variants represented in scores generated by LD-Pred-funct (≥3.5M variants).

Table 1: Cohort Characteristics				
Cohort	**Age (±SD)**	**Sex (% female)**	**N HTN Case**	**N HTN Control**
Optimization				
REGARDS AAs	63.59 (9.20)	60.98%	6146	2457
REGARDS EAs	68.34 (10.38)	42.30%	896	637
Validation				
HyperGEN AAs	47.01 (12.81)	63.52%	1315	581
HyperGEN EAs	49.83 (13.94)	50.47%	697	573
AA-African American, EA-European American, HTN-Hypertension				

Table 2: Variants Count by Method and LD Panel				
Cohort	**Ancestry**	**PRS Method**	**LD Panel**	**Variants Count**
REGARDS	EA	PRS-CS	HM3	1,096,331
	AA		HM3	1,198,248
HyperGEN	EA		HM3	886,230
	AA		HM3	1,173,942
REGARDS	EA		TagIt	1,428,183
	AA		TagIt	1,855,205
HyperGEN	EA		TagIt	1,102,428
	AA		TagIt	1,815,423
REGARDS	EA	LDPred-funct	HM3	4,538,902
	AA		HM3	4,003,542
HyperGEN	EA		HM3	3,530,155
	AA		HM3	3,784,296
AA-African American, EA-European American, HTN-Hypertension, LD-linkage disequilibrium, HM3-HapMap 3, TagIt-Tag(ging) It(erative) of SNPs				

The results represented as OR per SD of the PRS optimized in REGARDS and tested in HyperGEN are presented in **Table 3**. Based on R^2 the Phi of $1x10^{-04}$ was tested in PRS-CS in HyperGEN. Effect sizes and R^2 were higher in EAs compared to AAs in both REGARDS and HyperGEN across each method. For instance, the OR for LD-Pred-funct in HyperGEN EAs was 2.14 (95% CI: 1.61-2.85) versus 1.37 (95% CI: 1.19-1.58) for AAs. In both ancestry groups, scores created by adding functional priors (LDPred-funct) and expanding the reference panel (PRS-CS-TagIt) had improved R^2 compared to PRS-CS-HM3. We observed R^2 of 6.0% for LD-Pred-funct and R^2 of 7.3% for PRS-CS-TagIt in EAs from HyperGEN versus R^2 of 1.4% for PRS-CS-HM3 (**Table 3**). Among AAs in HyperGEN, the improvements were more modest, where we

observed R^2 of 1.9% for LD-Pred-funct and R^2 of 2.9% for PRS-CS-TagIt versus 0.7% for PRS-CS-HM3. See **Figure 2** for comparisons of R^2 by model by cohort. See **Supplementary Table 1** for the full results for each model for each cohort.

Table 3: HTN Results per 1 standard Deviation of the PRS

Cohort	PRS Method	Parameter	OR (95% CI)	P	R^2	AUC PRS
REGARDS EAs	PRS-CS-HM3	$1x10^{-04}$*	1.37 (1.23-1.53)	1.02E-08	2.71E-02	0.58
	PRS-CS-TagIt	$1x10^{-04}$*	1.73 (1.54-1.94)	4.48E-21	7.79E-02	0.64
	LDPred-funct	-	1.51 (1.35-1.68)	3.74E-13	4.46E-02	0.61
HyperGEN EAs	PRS-CS-HM3	$1x10^{-04*}$	1.40(1.07-1.82)	1.19E-02	1.37E-02	0.56
	PRS-CS-TagIt	$1x10^{-04*}$	2.17 (1.65-2.85)	3.00E-08	7.25E-02	0.61
	LDPred-funct	-	2.14 (1.61-2.85)	1.46E-07	6.03E-02	0.60
REGARDS AAs	PRS-CS-HM3	$1x10^{-04}$*	1.25 (1.19-1.32)	1.39E-16	1.76E-02	0.56
	PRS-CS-TagIt	$1x10^{-04}$*	1.28 (1.21-1.35)	5.36E-19	2.06E-02	0.57
	LDPred-funct	-	1.32 (1.25-1.39)	5.20E-24	2.66E-02	0.57
HyperGEN AAs	PRS-CS-HM3	$1x10^{-04}$*	1.20 (1.04-1.39)	1.15E-02	6.70E-03	0.53
	PRS-CS-TagIt	$1x10^{-04}$*	1.47 (1.27-1.69)	1.14E-07	2.94E-02	0.55
	LDPred-funct	-	1.37 (1.19-1.58)	1.76E-05	1.93E-02	0.52

*Best model Phi REGARDS, AA-African American, EA-European American, HM3-HapMap 3 LD Panel, TagIt-Tag(ging) It(erative) of SNPs LD Panel, AUC-Area Under the Curve



Figure 2. HTN R^2-liability comparison by method per 1 SD of PRS.

PRS threshold results (e.g. top 2% of the PRS distribution versus bottom 98%), are presented in **Supplementary Tables 1a** and **1b** in REGARDS EAs and AAs and **Supplementary Tables 2a** and **2b** for HyperGEN EAs and AAs, respectively. The PRS-CS-TagIt panel and LD-Pred-funct models had stronger associations with HTN at the four tested thresholds than the PRS-CS-HM3 model. For example, being in the top 5% of the PRS distribution for the score generated in LD-Pred-funct was associated with OR=8.10 (95% CI:2.48-26.51) and $p=5.4x10^{-04}$ in HyperGEN EAs. The comparable model for PRS-CS-TagIt (phi $1x10^{-04}$), for the 5% threshold had OR=7.98 (95% CI: 2.27-28.00) and $p=1.2x10^{-03}$. The AUC for the PRS-only model was 0.52 for both approaches (LD-Pred-funct and PRS-CS-TagIt) for the 5% threshold. The 5% threshold PRS-CS-HM3 model for EAs in HyperGEN was not significant ($p=1.4x10^{-01}$). Generally, across the models in HyperGEN EAs sensitivity was low

169 (<13.5%) and specificity was high (>0.86). The adjusted PPVs ranged 0.32-0.77 and the
170 adjusted NPVs ranged 0.43-0.47. For HyperGEN AAs for LD-Pred-funct the 5% threshold
171 model had an OR of 2.50 (95% CI: 1.32-4.70) with $p=4.6*10^{-03}$. The comparable model for
172 PRS-CS-TagIt (phi $1x10^{-04}$) for the 5% threshold had OR=3.50 (95% CI: 1.72-7.09) and
173 $p=5.3x10^{-04}$. Additionally, the sensitivities and specificities reported were consistently low and
174 high, respectively for HyperGEN AAs (sensitivity <0.11 and specificity >0.88). ROC curves for
175 REGARDS and HyperGEN are presented in Supplementary Figure 1.
176
177
178
179
180 Discussion
181
182 PRS is increasingly popular given accessibility of large-scale GWAS summary data
183 resources as well as the potential for broad clinical applications. Thus far, clinical translation
184 remains limited, but methods are rapidly evolving. The first PRS approaches such as P+T
185 subset GWAS SNPs based on different thresholds of significance and LD, while later Bayesian
186 methods included a wider set of SNPs with more sophisticated modeling to improve the capture
187 of trait heritability. (5, 16, 17). Current methods can be especially limiting for underrepresented
188 groups and revised PRS development strategies are needed to ensure that new health
189 disparities are not created in implementing PRS.(17) Adding functional annotations may help
190 prioritize variants that are more consistent across ancestry groups.(18) Further, the standard
191 approaches have also relied on older LD reference panels that may not capture an accurate
192 representation of LD for diverse groups.(6, 11) In the current study we evaluated both functional
193 annotations and an updated reference panel for improved performance of PRS for HTN, a
194 common, heritable chronic disease in both EA and AAs. We found that both annotations and
195 the updated panel improved the scores in both race groups, but did not make the scores more
196 equitable across the groups.
197 The accuracy of PRS depends on several factors including the SNP selection and the

198 truthfulness of their estimated effect sizes. Given evidence suggesting that common causal
199 variants are likely to be shared across populations, it's been hypothesized that functional
200 annotations can be used to discriminate probable causal SNPs from other SNPs in high LD with
201 them for better genomic prediction. (11, 19-23) However, prioritizing these variants is
202 challenging because numerous common causal variants in LD, often with modest effect sizes,
203 underly complex traits. (24, 25) In our study the scores created by LDPred-funct had many more
204 variants (~3X more) than for PRS-CS which could have diluted the effects for more important
205 SNPs. For multi-ancestry and cross-ancestry prediction, the accuracy is additionally influenced
206 by how well the LD in the GWAS summary statistics population and the LD panel match the
207 optimization population. A mismatch can be an important contributor to the loss in PRS
208 prediction accuracy in cross and multi-ancestry settings. (26) Therefore, in addition to functional
209 annotations we also considered how updating the reference panel to a more diverse set of
210 variants/samples could improve PRS for HTN. To date, a popular Bayesian method has used
211 HM3 variants in 1000G LD data to construct PRS.(6) This was mostly aimed at managing
212 computational resources while capturing overrepresented European ancestry genetic variation
213 from large-scale GWAS summary data. However, HM3 variants are known to miss signals
214 specific to other ancestry groups. We tested whether an expanded reference panel that includes
215 a more diverse set of 1000G variants may overcome some of those issues by leveraging the
216 PRISM Consortium TagIt panel in PRS-CS that captures >1 million more SNPs than the PRS-
217 CS HM3 default panel.(13, 27) Our results show expanding the reference panel and functional
218 annotations both improved performance to a comparable degree in EAs. Data on changing out
219 the LD reference panel in PRS derivation is mixed given expansion.(11-13) One study showed
220 increasing the sample size of the representative LD reference dataset linearly improved R^2.(12)
221 In the context of T2D in the paper by Huerta-Chagoya et. al. PRS created with the TagIt panel
222 always outperformed scores created with the HM3 panel across 5 major ancestry groups
223 (African/African American (AFR), Admixed American (AMR), East Asian (EAS), European

224 (EUR), and South Asian (SAS)). Given the HM3 and TagIt panels should work well in EAs, we
225 considered the improved performance of the TagIt panel over the standard HM3 panel in PRS-
226 CS could be due to better representation of HTN variants in the TagIt panel. However, given the
227 complexity and large number of SNPs in the PRS fully characterizing how differences in HTN
228 SNP representation drive performance was beyond the scope of our project. Unfortunately,
229 neither an expanded reference panel or functional annotations improved PRS performance
230 much in AAs, highlighting an important trend that PRS generally are less accurate in minority
231 populations. This is likely mostly driven by underrepresentation in the summary statistic data
232 and the benefits of a more diverse LD reference panel may not be fully observed until training
233 data becomes more representative.

234 Multi-ancestry HTN PRS have largely been trained on continuous-trait BP summary
235 statistics for SBP and DBP, rather than solely on summary statistics for dichotomous HTN, as
236 we did in this study.(28) In one recent study, Kurniansyah *et al*. trained a HTN PRS using
237 GWAS summary statistics from over 50,000 diverse samples and a P+ T approach using GWAS
238 data for SBP, DBP, and HTN, respectively.(29) A PRS was optimized for each trait and the trait-
239 specific PRSs were joined via an unweighted sum called "PRSsum" estimating the HTN-PRS. In
240 the validation phase of that study using over 30,000 participants from BioMe, the HTN-PRS had
241 an OR=1.32 per SD (95% CI: 1.2-1.4) for prevalent HTN in 8723 AAs and OR=1.47 per SD
242 (95% CI: 1.4-1.5) in 22463 EAs. In another study, that same PRS had OR=1.27 per SD (95%
243 CI 1.2-1.3) for prevalent HTN in a combined race sample of 98,590 from the All of Us network
244 (~20% AA). (28) Overall, there has been a lot of research focused on optimizing PRS for HTN in
245 diverse groups. In a multi-ancestry investigation of multiple BP PRS created by "clumping-and-
246 thresholding" (PRSice2), LDPred2 as well as PRS-CSx (a multi-ancestry modification of PRS-
247 CS), the PRS-CSx approach performed best across all race/ethnic backgrounds. They showed
248 that R^2 values for BP in AA participants were comparable to estimates reported in our study ~3-
249 3.5%.(28) Generally, the scores we developed in this study only improved marginally on

250 previous publications. The body of evidence shows multi-trait training data, multi-ancestry
251 representation in the summary data, modeling functional annotations, and improvements to the
252 reference LD panel all increase HTN PRS performance in EAs and AAs.(28, 29) As summary
253 statistic datasets grow and diversify, annotations improve, and computing resources expand
254 PRS, the gap in PRS performance between AAs and EAs for HTN should narrow.

255 This study developed PRS for HTN in well-characterized cohorts with EA and AA adults
256 with relevant genetic data from the REGARDS study. The scores developed were then tested
257 in a familial study of HTN (HyperGEN) with comparable phenotypic and genetic data resources.
258 We leveraged a novel LD reference panel developed by the PRISM Consortium, an NIH-funded
259 program that investigates the transportability of PRS. Limitations included that the multi-
260 ancestry summary statistics were predominantly derived from the UKB EA population, although
261 that dataset does have samples from multiple ancestry groups. In our testing cohort,
262 HyperGEN, some of the thresholded models had smaller participant counts (e.g. only 12
263 controls were in the top 5% for EAs) which likely inflated some of the OR estimates and made
264 confidence intervals around those estimates wide. Finally, given we only studied the EA and AA
265 populations, our work may not be generalizable to other ancestry groups.

266 In summary, we constructed multiple PRSs for HTN using Bayesian approaches
267 incorporating millions of SNPs for risk prediction. We showed that updating the reference panel
268 in PRS-CS and adding functional priors in LDPred-funct can improve HTN PRS performance.
269 While validation of the scores showed comparability and/or marginal improvement over
270 published data, the results still illustrate the difficulty of constructing PRS that can be clinically
271 informative. Expanding non-European genomic resources while leveraging the growing publicly
272 available annotation data, especially at the tissue and cell level is needed to continue to move
273 the field forward. Further, studies linking PRS to incident HTN will be necessary to evaluate if
274 scores for this common condition can aid in prevention and treatment.
275

Methods

Study populations

REGARDS is a national cohort established for the study of incident stroke and associated risk factors. Between 2003 and 2007 over 30,239 AA and EA adults aged 45 years or older were enrolled from all 48 contiguous US states and the District of Columbia.(30) At baseline, participants completed a computer-assisted telephone interview followed by an in-home visit that assessed blood pressure and other clinical measurements. REGARDS is ongoing and since its inception, participants have been contacted at six-month intervals to obtain information regarding incident stroke and secondary cardiovascular outcomes. HyperGEN was a cross-sectional, population-based study designed to identify genetic risk factors for HTN and target end-organ damage due to HTN.(31) The cohort, composed of self-reported AA and EA sibships, was recruited from five field centers across the US (Forsyth County, NC; Minneapolis, MN; Framingham, MA; Salt Lake City, UT; and Birmingham, AL). Recruitment included sibling probands who were diagnosed with HTN before age 60, their unmedicated adult offspring, and age-matched controls. In a later recruitment phase other siblings of the original sibling pair as well as their children were included for a total sample size of N=4584.

Informed consent was obtained from all subjects involved in the HyperGEN and REGARDS studies. The REGARDS study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of the University of Alabama at Birmingham (UAB IRB protocol number: IRB-020925004). The HyperGEN study was approved by the same IRB (UAB IRB protocol number: IRB-160331004). The PRS research leveraging these datasets was approved by UAB IRB protocol number: IRB-300006721.

305 *Genotyping*
306
307 A subset of 10,788 AA and EA REGARDS participants underwent genotyping using the
308 Illumina Infinium AMR/AFR (MEGA) BeadChip array. Quality control procedures have been
309 previously described, but briefly, internal duplicates and HapMap controls were excluded, as
310 well as samples whose genetic sex did not match the self-reported sex.(14) Variants were
311 excluded if they were located on sex chromosomes, had ambiguous strands, were not bi-allelic,
312 were in violation of Hardy Weinberg ($p<1.00E-12$ for AAs and $p<1.00E-5$ for EAs), and/or had a
313 missing rate >10%. Imputation in each ancestry separately was performed using the Trans-
314 Omics for Precision Medicine (TOPMed) release 2 (r2, Freeze 8) reference panel. (32) Imputed
315 variants were kept if r^2 >0.3 and genotypic probability >0.9. After QC a total of 6,146 AA HTN
316 cases and 2,457 AA controls contributed data to the analysis along with 896 and 637 EA HTN
317 cases and controls from REGARDS.
318
319 Genotyping of AA HyperGEN participants was performed through whole genome
320 sequencing (N=1,896).(33) In order to harmonize our imputation efforts with the array-based
321 panels of REGARDS, we subset common bi-allelic SNPs with MAF >1% overlapping with the
322 GWAS MEGA arrays used in REGARDS. This yielded a total of 2,204,415 SNPs that were used
323 as fence post variants for imputing the HyperGEN AA cohort using version r2 of the TOPMed
324 reference panel. Imputed variants were inspected for their imputation quality scores and
325 retained if r^2 >0.3 along with genotypic probability >0.9. HyperGEN EAs (N=1358) were
326 genotyped with the Affymetrix Genome-Wide Human SNP Array 6.0 (1.8 million variants).
327 Similarly to REGARDS, internal duplicates and HapMap controls were excluded, as well as
328 samples whose genetic sex did not match the self-reported sex. Variants were excluded if they
329 were located on sex chromosomes, had ambiguous strands, were not bi-allelic, were in violation
330 of Hardy Weinberg, and/or had a missing rate >10%. Imputation was performed using the
331 TOPMed r2 (Freeze 8) reference panel.(32) Imputed variants were retained if r^2 >0.3) and calls

332 had genotypic probability >0.9. After QC a total of 1315 and 581 AA HTN cases and controls
333 contributed data to the analysis, along with 697 and 573 EA HTN cases and controls from
334 HyperGEN.
335
336
337 *Phenotyping*
338
339 The measurement of blood pressure (BP) in the REGARDS study has been
340 described.(34) Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were defined
341 as the average of two measurements taken during the in-home visit by a trained technician
342 using a standardized protocol and regularly tested aneroid sphygmomanometer after the
343 participant was seated for five minutes. HTN was defined as SBP ≥140 and/or DBP ≥90 mmHg
344 and/or treatment with antihypertensive medication. The use of anti-hypertensive medication was
345 self-reported. In HyperGEN, BP measurements were made during the study visit, three times on
346 each arm. The participants rested for five minutes before measurement and 30 seconds
347 between measurements.(31) An average SBP and DBP were calculated based on the second
348 and third measurements in the second arm. Blood pressure measurements were obtained using
349 automated Dinamap devices (model 1846 SX/P, Critikon, Tampa, FL) to promote comparable
350 measurements among HyperGEN field centers. HTN was defined as average SBP ≥ 140 mmHg
351 or average DBP ≥ 90 mmHg, or using at least one class of antihypertensive medication.
352
353
354
355 *PRS construction and optimization*
356 The Bayesian methods applied require GWAS summary statistics, participant individual
357 level data for optimization and an external LD reference panel for PRS construction.(6, 11) We
358 leveraged Pan UK Biobank Multi-Ethnic GWAS summary statistics for HTN representing multi-
359 ancestry data from 420,473 European (EUR) individuals, 6,624 African (AFR) individuals, 8,849
360 South Asian (SAS) individuals, 2,707 East Asian (EAS) individuals, 998 Admixed American

361 (AMR), and 1,595 middle eastern ancestry individuals (MID).(35) For each PRS software
362 package, the REGARDS cohort served as the optimization cohort and HyperGEN as the
363 validation cohort.
364
365 We first applied PRS-CS using the HapMap3 (HM3) SNPs (default PRS-CS-HM3 LD
366 panel) [20] and a newly developed TagIt LD panel from the D-PRISM Consortium (developed
367 using the Tag(ging) It(erative) of SNPs in multiple populations (TagIt) program), designed to
368 enhance variants available for cross-ancestry prediction through leveraging variants and
369 samples from the 1000 Genomes project (PRS-CS-TagIt).(13, 27, 36, 37) The HM3 LD panel in
370 PRS-CS had 1,225,319 variants, whereas the expanded TagIt panel had 2,374,614 variants
371 with 729,110 overlapping between the two panels (6). To optimize the global scaling parameter
372 ϕ, we applied a grid search across four ϕ values (1.0, $1x10^{-02}$, $1x10^{-04}$, $1x10^{-06}$) in the
373 optimization sample. In addition, we applied LDpred-funct, which is distinct from PRS-CS since
374 it leverages trait-specific functional priors for coding, conserved, regulatory, and LD-related
375 annotations.(11) LDpred-funct then uses both the functional priors and information on the LD
376 between variants from a 1000G phase 3 reference panel (including 1,217,312 variants) to
377 estimate the posterior mean causal effect sizes. To improve computational efficiency, we ran
378 the LDpred-funct program chromosome by chromosome. This allowed us to calculate weights at
379 the chromosomal level and then combine them for validation. As an input parameter, SNP-
380 heritability was calculated using LD score regression (LDSC). (38) See **Figure 1** for an outline
381 of our pipelines for each PRS development approach.
382
383
384
385



Figure 1. PRS Pipeline.

In total, we generated 20 PRSs for HTN in the REGARDS data (10 for each ancestry group, where 4 (one for each ϕ) were output for PRS-CS-HM3, 4 (one for each ϕ) for PRS-CS-TagIt, and 2 (raw and p-value based) for LD-Pred-funct). The predictive performance of each PRS was assessed via a range of metrics. To measure the overall prediction accuracy, we calculated the proportion of variation in the trait explained by the PRS on the liability scale (R^2 liability) after accounting for a basic set of covariates, including age, sex, and the top 10 ancestry principal components (PCs).(39, 40) Additionally, we calculated the area under the curve (AUC) for a covariates-only model (age, sex, and top 10 PCs), a PRS-only model, and a combined model (PRS plus covariates); and the odds ratio (OR) per standard deviation (OR/SD) change in the PRS, as well as the thresholded ORs (top 2%, 5%, or 10% of the PRS distribution relative to the remaining participants). Sensitivity, specificity, positive predictive value (PPV; the proportion of identified high-risk individuals who are true HTN case subjects), and negative predictive value (NPV; the proportion of unidentified individuals that are HTN

control subjects) are also reported. Since PPV and NPV depend on the prevalence of the disease (we used 50% for both EAs and AAs), we report prevalence-adjusted PPV and NPV similarly to a previous report.(41) We tested all the same metrics for the 10 scores in each ancestry group in the HyperGEN cohort. All HyperGEN models were mixed models accounting for familial relatedness. For all PRS-CS models the best ϕ value score for REGARDS as determined by highest R^2 are presented in the main tables and is the focus of the validation in HyperGEN.

Supplemental Figure 1. AUC comparison for prediction of HTN. A) AUC comparisons in AA participants from REGARDS optimization cohort. B) AUC comparisons in AA participants from HyperGEN validation cohort. C) AUC comparisons in EA participants from REGARD optimization cohort. D) AUC comparisons in EA participants from HyperGEN validation cohort

447 Literature Cited
448
449 1. Schunkert H, Di Angelantonio E, Inouye M, Patel RS, Ripatti S, Widen E, et al. Clinical
450 utility and implementation of polygenic risk scores for predicting cardiovascular disease: A
451 clinical consensus statement of the ESC Council on Cardiovascular Genomics, the ESC
452 Cardiovascular Risk Collaboration, and the European Association of Preventive Cardiology. Eur
453 Heart J. 2025;46(15):1372-83.
454 2. Lennon NJ, Kottyan LC, Kachulis C, Abul-Husn NS, Arias J, Belbin G, et al. Selection,
455 optimization and validation of ten chronic disease polygenic risk scores for clinical
456 implementation in diverse US populations. Nat Med. 2024;30(2):480-7.
457 3. Lewis CM, Vassos E. Polygenic risk scores: from research tools to clinical instruments.
458 Genome Med. 2020;12(1):44.
459 4. Ni G, Zeng J, Revez JA, Wang Y, Zheng Z, Ge T, et al. A Comparison of Ten Polygenic
460 Score Methods for Psychiatric Disorders Applied Across Multiple Cohorts. Biol Psychiatry.
461 2021;90(9):611-20.
462 5. Choi SW, O'Reilly PF. PRSice-2: Polygenic Risk Score software for biobank-scale data.
463 Gigascience. 2019;8(7).
464 6. Ge T, Chen CY, Ni Y, Feng YA, Smoller JW. Polygenic prediction via Bayesian
465 regression and continuous shrinkage priors. Nat Commun. 2019;10(1):1776.
466 7. Lloyd-Jones LR, Zeng J, Sidorenko J, Yengo L, Moser G, Kemper KE, et al. Improved
467 polygenic prediction by Bayesian multiple regression on summary statistics. Nat Commun.
468 2019;10(1):5086.
469 8. Prive F, Arbel J, Vilhjalmsson BJ. LDpred2: better, faster, stronger. Bioinformatics.
470 2021;36(22-23):5424-31.
471 9. Vilhjalmsson BJ, Yang J, Finucane HK, Gusev A, Lindstrom S, Ripke S, et al. Modeling
472 Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores. Am J Hum Genet.
473 2015;97(4):576-92.
474 10. Jiang W, Chen L, Girgenti MJ, Zhao H. Tuning parameters for polygenic risk score
475 methods using GWAS summary statistics from training data. Nat Commun. 2024;15(1):24.
476 11. Marquez-Luna C, Gazal S, Loh PR, Kim SS, Furlotte N, Auton A, et al. Incorporating
477 functional priors improves polygenic prediction accuracy in UK Biobank and 23andMe data sets.
478 Nat Commun. 2021;12(1):6052.
479 12. Zheng Z, Liu S, Sidorenko J, Wang Y, Lin T, Yengo L, et al. Leveraging functional
480 genomic annotations and genome coverage to improve polygenic prediction of complex traits
481 within and between ancestries. Nat Genet. 2024;56(5):767-77.
482 13. Huerta-Chagoya A, Kim J, Mandla R, Lu Y, Suzuki K, Petty LE, et al. Multi-ancestry
483 polygenic risk scores for the prediction of type 2 diabetes and complications in diverse
484 ancestries. medRxiv. 2025.
485 14. Armstrong ND, Srinivasasainagendra V, Patki A, Tanner RM, Hidalgo BA, Tiwari HK, et
486 al. Genetic Contributors of Incident Stroke in 10,700 African Americans With Hypertension: A
487 Meta-Analysis From the Genetics of Hypertension Associated Treatments and Reasons for
488 Geographic and Racial Differences in Stroke Studies. Front Genet. 2021;12:781451.
489 15. Jones AC, Patki A, Srinivasasainagendra V, Tiwari HK, Armstrong ND, Chaudhary NS,
490 et al. Single-Ancestry versus Multi-Ancestry Polygenic Risk Scores for CKD in Black American
491 Populations. J Am Soc Nephrol. 2024;35(11):1558-69.
492 16. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation
493 PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4:7.
494 17. Ndong Sima CAA, Step K, Swart Y, Schurz H, Uren C, Moller M. Methodologies
495 underpinning polygenic risk scores estimation: a comprehensive overview. Hum Genet.
496 2024;143(11):1265-80.
497 18. Norland K, Schaid DJ, Kullo IJ. Enhancing polygenic scores for cardiometabolic traits

through tissue- and cell-type-specific functional annotations. HGG Adv. 2025;6(3):100427.
19. Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat Genet. 2019;51(4):584-91.
20. Yengo L, Vedantam S, Marouli E, Sidorenko J, Bartell E, Sakaue S, et al. A saturated map of common genetic variants associated with human height. Nature. 2022;610(7933):704-12.
21. Schaid DJ, Chen W, Larson NB. From genome-wide associations to candidate causal variants by statistical fine-mapping. Nat Rev Genet. 2018;19(8):491-504.
22. Patxot M, Banos DT, Kousathanas A, Orliac EJ, Ojavee SE, Moser G, et al. Probabilistic inference of the genetic architecture underlying functional enrichment of complex traits. Nat Commun. 2021;12(1):6972.
23. Hu Y, Lu Q, Powles R, Yao X, Yang C, Fang F, et al. Leveraging functional annotations in genetic risk prediction for human complex diseases. PLoS Comput Biol. 2017;13(6):e1005589.
24. O'Connor LJ, Schoech AP, Hormozdiari F, Gazal S, Patterson N, Price AL. Extreme Polygenicity of Complex Traits Is Explained by Negative Selection. Am J Hum Genet. 2019;105(3):456-76.
25. Zeng J, de Vlaming R, Wu Y, Robinson MR, Lloyd-Jones LR, Yengo L, et al. Signatures of negative selection in the genetic architecture of human complex traits. Nat Genet. 2018;50(5):746-53.
26. Kachuri L, Chatterjee N, Hirbo J, Schaid DJ, Martin I, Kullo IJ, et al. Principles and methods for transferring polygenic risk scores across global populations. Nat Rev Genet. 2024;25(1):8-25.
27. Mercader JM, Ng MCY, Manning AK, Rich SS. Predicting diabetes risk in diverse populations: what next? Lancet Diabetes Endocrinol. 2021;9(12):808-10.
28. Kurniansyah N, Goodman MO, Khan AT, Wang J, Feofanova E, Bis JC, et al. Evaluating the use of blood pressure polygenic risk scores across race/ethnic background groups. Nat Commun. 2023;14(1):3202.
29. Kurniansyah N, Goodman MO, Kelly TN, Elfassy T, Wiggins KL, Bis JC, et al. A multi-ethnic polygenic risk score is associated with hypertension prevalence and progression throughout adulthood. Nat Commun. 2022;13(1):3549.
30. Howard VJ, Cushman M, Pulley L, Gomez CR, Go RC, Prineas RJ, et al. The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology. 2005;25(3):135-43.
31. Williams RR, Rao DC, Ellison RC, Arnett DK, Heiss G, Oberman A, et al. NHLBI family blood pressure program: methodology and recruitment in the HyperGEN network. Hypertension genetic epidemiology network. Ann Epidemiol. 2000;10(6):389-400.
32. Das S, Forer L, Schonherr S, Sidore C, Locke AE, Kwong A, et al. Next-generation genotype imputation service and methods. Nat Genet. 2016;48(10):1284-7.
33. Kelly TN, Sun X, He KY, Brown MR, Taliun SAG, Hellwege JN, et al. Insights From a Large-Scale Whole-Genome Sequencing Study of Systolic Blood Pressure, Diastolic Blood Pressure, and Hypertension. Hypertension. 2022;79(8):1656-67.
34. Howard G, Cushman M, Moy CS, Oparil S, Muntner P, Lackland DT, et al. Association of Clinical and Social Factors With Excess Hypertension Risk in Black Compared With White US Adults. JAMA. 2018;320(13):1338-48.
35. Parcha V, Pampana A, Shetty NS, Irvin MR, Natarajan P, Lin HJ, et al. Association of a Multiancestry Genome-Wide Blood Pressure Polygenic Risk Score With Adverse Cardiovascular Events. Circ Genom Precis Med. 2022;15(6):e003946.
36. Kullo IJ, Conomos MP, Nelson SC, Adebamowo SN, Choudhury A, Conti D, et al. The PRIMED Consortium: Reducing disparities in polygenic risk assessment. Am J Hum Genet. 2024;111(12):2594-606.

37. Wojcik GL, Fuchsberger C, Taliun D, Welch R, Martin AR, Shringarpure S, et al. Imputation-Aware Tag SNP Selection To Improve Power for Large-Scale, Multi-ethnic Association Studies. G3 (Bethesda). 2018;8(10):3255-67.
38. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Schizophrenia Working Group of the Psychiatric Genomics C, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet. 2015;47(3):291-5.
39. Lee SH, Wray NR, Goddard ME, Visscher PM. Estimating missing heritability for disease from genome-wide association studies. Am J Hum Genet. 2011;88(3):294-305.
40. Lee SH, Goddard ME, Wray NR, Visscher PM. A better coefficient of determination for genetic profile analysis. Genet Epidemiol. 2012;36(3):214-24.
41. Irvin MR, Ge T, Patki A, Srinivasasainagendra V, Armstrong ND, Davis B, et al. Polygenic Risk for Type 2 Diabetes in African Americans. Diabetes. 2024;73(6):993-1001.

Funding/Support: This study was directly supported by National Institutes of Health (NIH) and National Heart, Lung, and Blood Institute grants (R01HL136666 and R35HL155466, MRI). The parent REGARDS study was supported by a cooperative agreement (U01NS041588) from the National Institute of Neurological Disorders and Stroke, the NIH, and the US Department of Health and Human Services. J.M.M. is supported by American Diabetes Association grant #11-22-ICTSPM-16 and by NHGRI U01HG011723, by the National Institute Of Diabetes And Digestive And Kidney Diseases of the National Institutes of Health under Award Number R01DK137993 and U01 DK140757, AMP CMD award from RFP 6 from the Foundation for the National Institutes of Health, and a Medical University of Bialystok (MUB) grant from the Ministry of Science and Higher Education (Poland). This work is supported by the Novo Nordisk Foundation (NNF21SA0072102). Z.W was supported by the National Heart, Lung, and Blood Institute (K01HL171839)